VER-01

Phase 3Small molecule

VVertanical GmbH

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Lumbosacral RadiculopathyNot yet recruiting

Lumbosacral RadiculopathyPhase 3

Not yet recruiting

Timeline

Expected Milestones

Q3 2028

Phase 3Not yet recruiting

Lumbosacral Radiculopathy

NCT06956014

Clinical

Trials by Indication[1]

Low back pain3 trials

Dose-Response Characterization of VER-01 in the Treatment of Patients With Chronic Non-specific Low Back Pain

Completed·VVertanical GmbH·Phase 2·NCT06475001·652 enrolled

Efficacy and Safety of VER-01 in the Treatment of Patients With Chronic Non-specific Low Back Pain

Completed·VVertanical GmbH·Phase 3·NCT04940741·820 enrolled

Comparison of VER-01 to Opioids in Patients With Chronic Non-specific Low Back Pain

Completed·VVertanical GmbH·Phase 3·NCT05610813·384 enrolled

Lumbosacral Radiculopathy1 trial

Multicenter, Double-blind, Randomized, Placebo-controlled Phase III Trial to Evaluate the Efficacy and Safety of the Full-spectrum Cannabis Extract VER-01 in Participants With Chronic Painful Lumbosacral Radiculopathy

Not yet recruiting·VVertanical GmbH·Phase 3·NCT06956014·810 enrolled

Unspecified2 trials

Food Effect Study of VER-01 in Healthy Volunteers

Completed·VVertanical GmbH·Phase 1·NCT04930796·18 enrolled

Single and Multiple Dose Study of VER-01 in Healthy Volunteers

Completed·VVertanical GmbH·Phase 1·NCT04930809·42 enrolled

Sources

References

[1]
ClinicalTrials.gov — 6 trial records for VER-01. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — VER-01 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for VER-01. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Vertanical GmbH company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: VVertanical GmbH